hVIVO plc Directors' Dealings (2006G)
August 04 2016 - 2:01AM
UK Regulatory
TIDMHVO
RNS Number : 2006G
hVIVO plc
04 August 2016
For immediate release 7.00am: 4 August 2016
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), the pioneer of human disease models,
announces that application has been made to AIM for the admission
of 9,946 new ordinary shares of 5.0p each in the Company (the "New
Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jaime Ellertson (Non-Executive Chairman) and Jim
Winschel (Non-Executive Director) of new ordinary shares, under the
terms of their letters of appointment as set out in the Company's
announcement of 4 November 2014 which stated that Mr Ellertson and
Mr Winschel had entered into binding commitments to purchase
$20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively
per quarter. The New Ordinary Shares represent their investments
for the quarter ended 30 June 2016. On 3 August 2016, Mr Ellertson
invested in an additional 7,801 ordinary shares and Mr Winschel
invested in an additional 2,145 ordinary shares, at a price of
186.5 pence per share.
Following admission of the 9,946 New Ordinary Shares to trading
on AIM, the total number of ordinary shares with voting rights in
issue will be 78,080,185 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 9 August 2016. Following
Admission, Mr Ellertson and Mr Winschel will be interested in a
total of 46,494 and 32,485 ordinary shares of 5.0p in the Company
respectively, each representing less than 0.1% of the Company's
issued share capital.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO is a life sciences company pioneering a technology
platform of human disease models to accelerate drug discovery and
development in respiratory and infectious diseases, including RSV,
flu, asthma, and common cold. hVIVO has commercialised four disease
models, successfully enrolled over 2,100 subjects and conducted
over 40 product validation studies for a wide range of industry,
government and academic clients and collaborators.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUGUMGRUPQPGW
(END) Dow Jones Newswires
August 04, 2016 02:01 ET (06:01 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Oct 2023 to Oct 2024